Supplementary figure 2 | Influence of caspase inhibitor on integrity of cell-free synthesized EGFReYFP. IRES-mediated synthesis of EGFR-eYFP in the presence of poly G was performed for 24 hours with (a) and without the caspase inhibitor Z-VAD-FMK (b). Samples were taken at the indicated time points and separated by electrophoresis followed by autoradiography. Isotopic labeling was achieved by 14 C-leucine supplementation. Supplementary figure 3 | Reaction lifetime of IRES-mediated synthesis in the presence of poly G. The synthesis of EGFR-eYFP was performed for 180 minutes. Samples were taken at the indicated time points, total protein was precipitated by hot TCA precipitation and analyzed by β-scintillation counting. Isotopic labeling was achieved by 14 C-leucine supplementation. IRESmediated cell-free synthesis of EGFR-eYFP was performed in the presence of different amounts of microsomes, whereas 100% represents the standard microsome amount used during this study. Isotopic labeling was achieved by 14 C-leucine supplementation. Microsomal fractions of the different cell-free reactions containing 50%, 100%, 250% and 500% microsomes were either washed with PBS or urea (4.5 M urea in PBS). The washing step was performed by pipetting the microsomes up and down until a homogenous solution was obtained followed by incubation on ice for 30 min. Samples were subsequently centrifuged and the resulting supernatant (S) and washed microsomal fraction (M) were analyzed by autoradiography and β-scintillation counting. M pre-wash: Analysis of microsomal fraction before the washing step. Error bars represent the standard deviation of triplicate analysis.
Supplementary figure 5 | Western Blot (a and b) and autoradiograph (c) of microsomal fractions with EGFR-eYFP after incubation in kinase buffer. IRES-mediated cell-free synthesis of EGFR-eYFP was performed in presence of different amounts of microsomes, whereas 100% represents the standard microsome amount used during this study. Isotopic labeling was achieved by 14 C-leucine supplementation. Western blot membranes were blocked in TBS buffer containing 2% BSA and 0.1% Tween-20 for 1 hour and subsequently incubated with "EGF Receptor (D38B1) XP® Rabbit mAb 4267" or "Phospho-EGF Receptor (Tyr1068) (D7A5) XP® Rabbit mAb 3777" primary antibodies diluted 1:1000 over night at 4°C. "Anti-rabbit IgG, HRP-linked Antibody 7074" diluted 1:2000 was used as a secondary antibody and detection was carried out using the "Amersham ECL Select Western Blotting Detection Reagent" (GE Healthcare) and the "Typhoon Trio+ Variable Mode Imager" (GE Healthcare). Western blot membranes shown in (a) were scanned simultaneously, while the membranes depicted in (b) were scanned one after another and have been adapted in contrast and brightness for better visibility of faint bands. The autoradiograph shown in (c) corresponds to the western blot membrane depicted in (a) and (b). figure  5b and c, respectively.
